

Contents

Preface *XXIII*

List of Contributors *XXV*

Part One Biochemistry and Molecular Genetics of Drug Metabolism 1

- 1 Drug-Metabolizing Enzymes—An Overview 3**
Pavel Anzenbacher and Eva Anzenbacherová
- 1.1 Introduction: Fate of a Drug in the Human Body 3
- 1.2 Classification Systems of Drug-Metabolizing Enzymes According to Different Criteria 4
- 1.3 Overview of the Most Important Drug-Metabolizing Enzymes 6
- 1.3.1 CYPs 6
- 1.3.2 Peroxidases 8
- 1.3.3 Flavin Monooxygenases 10
- 1.3.4 Other Oxidases: Amine Oxidases, and Molybdenum-Containing XO and AO 11
- 1.3.5 NADPH Oxidase, NAD(P)H Oxidoreductase, and Dihydropyridine Dehydrogenase 13
- 1.3.6 Reductases 14
- 1.3.7 Conjugating Enzymes 15
- Acknowledgments 20
- References 20
- 2 Cytochromes P450 27**
F. Peter Guengerich
- 2.1 Introduction and Historical Perspective 27
- 2.2 Nomenclature and Gene Organization 29
- 2.3 Regulation 32
- 2.3.1 Transcriptional Regulation 32
- 2.3.2 Post-Translational and Epigenetic Regulation 34
- 2.3.3 Post-Translational Regulation 34

2.4	Polymorphisms	35
2.5	Protein Structure	37
2.6	Catalytic Mechanisms	40
2.7	What Determines P450 Catalytic Selectivity?	45
2.8	Oxidative Stress and P450s	47
2.9	Relevance in Drug Metabolism and Clinical Medicine	48
	References	53
3	UDP-Glucuronosyltransferases	67
	<i>Christian P. Strassburg and Sandra Kalthoff</i>	
3.1	Introduction	67
3.2	A Simple Phenotype: Unconjugated Nonhemolytic Hyperbilirubinemia and Glucuronidation	67
3.3	Organization of UGTs and the <i>UGT1A</i> Gene Locus	68
3.4	<i>UGT1A</i> Gene Nomenclature	70
3.5	Human <i>UGT1A</i> Gene Locus and Sequence Variability	71
3.6	Glucuronidation of Bilirubin	78
3.7	<i>UGT1A1</i> Gene	79
3.8	Is There an Advantage or Risk Associated with <i>UGT1A1</i> Variability?	80
3.9	<i>UGT1A1</i> Gene and Pharmacogenetic Protection	82
3.9.1	Cardiovascular Disease	82
3.9.2	Cancer	82
3.10	<i>UGT1A1</i> Gene and Pharmacogenetic Risks	83
3.10.1	Disposition to Drug Toxicity	83
3.10.1.1	Irinotecan Toxicity	83
3.10.1.2	Jaundice in Protease Inhibitor Therapy (Atazanavir and Indinavir)	86
3.11	<i>UGT1A1</i> Variability and Cancer Risk	86
3.11.1	CRC	87
3.11.2	Breast Cancer	87
3.12	<i>UGT1A3</i> Gene	87
3.13	<i>UGT1A7</i> Gene	88
3.13.1	CRC	93
3.13.2	HCC	93
3.13.3	Pancreatic Cancer	94
3.14	Transcriptional Regulation of <i>UGT1A</i> Genes	95
3.15	Aryl Hydrocarbon Receptor/Aryl Hydrocarbon Receptor Nuclear Translocator Regulation of <i>UGT1A</i> Genes	95
3.16	Regulation by Hepatic Nuclear Factors	97
3.17	Regulation by the Farnesoid X Receptor	97
3.18	Regulation by Nuclear Factor Erythroid 2-Related Factor 2	98
3.19	Regulation by Splice Variants	98
3.20	Animal Models to Study <i>UGT1A</i> Genes	99
3.21	Outlook	100

	Acknowledgments	101
	References	101
4	Sulfotransferases	117
	<i>Michael W. H. Coughtrie</i>	
4.1	Introduction	117
4.2	Background	118
4.3	PAPS Synthesis	119
4.4	SULT Enzyme Family	121
4.4.1	SULT1 Family	121
4.4.2	SULT2 Family	126
4.4.3	SULT3, 4, 5 and 6 Families	127
4.5	Assays for SULT Activity	128
4.6	Structure and Function of SULT	128
4.7	SULT Pharmacogenetics	132
4.8	Bioactivation and the Role of SULTs in Toxicology	133
4.9	Conclusions and Future Perspectives	135
	References	135
5	Glutathione S-Transferases	147
	<i>Miroslav Dostalek and Anna-Katarina Stark</i>	
5.1	Introduction and History	147
5.2	Nomenclature, Structure, and Function	148
5.2.1	Cytosolic GSTs	148
5.2.1.1	GSTA, GSTM, and GSTP Classes	149
5.2.1.2	GSTS Class	149
5.2.1.3	GSTT Class	149
5.2.1.4	GSTO Class	150
5.2.1.5	GSTZ Class	150
5.2.2	Mitochondrial GSTs	150
5.2.3	Microsomal GSTs	150
5.3	Substrates	151
5.4	Regulation, Induction, and Inhibition	151
5.5	Gene Polymorphism of GSTs	155
5.5.1	GSTA Polymorphism	156
5.5.2	GSTM Polymorphism	156
5.5.3	GSTT Polymorphism	156
5.5.4	GSTP1 Polymorphism	157
5.5.5	GSTO Polymorphism	157
	References	157
6	Hydrolytic Enzymes	165
	<i>Bingfang Yan</i>	
6.1	Carboxylesterases	165
6.1.1	Overview	165

6.1.2	Classification and Structural Features	166
6.1.2.1	Human Carboxylesterases	166
6.1.2.2	Salient Features of Carboxylesterases	167
6.1.2.3	Secondary and Crystal Structure	167
6.1.3	Catalytic Mechanism, Substrate Specificity, and Activators and Inhibitors	168
6.1.3.1	Catalytic Mechanism	168
6.1.3.2	Substrate Specificity	169
6.1.3.3	Activators and Inhibitors	170
6.1.4	Pharmacogenomics of Carboxylesterases	172
6.1.4.1	Polymorphisms	173
6.1.4.2	Interaction with the Cytochrome P450 Enzyme System	173
6.1.4.3	Interaction with UDP-Glucuronosyltransferases	174
6.1.4.4	Interactions with Drug Transporters	175
6.1.4.5	Drug–Insecticide Interactions	175
6.1.5	Comparison between Human and Animal Carboxylesterases	175
6.1.5.1	Tissue Distribution	176
6.1.5.2	Species-Specific Hydrolysis	176
6.1.5.3	Ontogenic Expression	177
6.1.5.4	Regulated Expression	177
6.2	Epoxide Hydrolases	178
6.2.1	Overview	178
6.2.2	Classification and Structural Features	179
6.2.3	Catalytic Mechanisms	180
6.2.4	Comparison among Various EHs	181
6.3	Paraoxonases	183
6.3.1	Overview	183
6.3.2	Classification and Structural Features	184
6.3.3	Catalytic Mechanism	185
6.4	Other Hydrolases	188
6.4.1	Carbonic Anhydrases	188
6.4.2	Cholinesterases	188
6.4.3	β -Glucuronidase	189
6.4.4	Lipases	190
6.4.5	Peptidases/Proteases	190
6.4.6	Valacyclovirase	190
	References	191
7	Transporting Systems	199
	<i>Anne T. Nies, Claudia Resch, and Tadashi Namisaki</i>	
7.1	Introduction	199
7.2	Classification of Drug Transporters and Transport Mechanisms	199
7.3	Drug Transporters of the SLC Superfamily	200
7.4	ABC Drug Transporters	208

- 7.5 Drug Transporters and Disease 208
- 7.6 Drug Transporters and Pharmacokinetics 212
- 7.6.1 Intestinal Transporters 212
- 7.6.2 Hepatic Transporters 213
- 7.6.3 Renal Transporters 213
- 7.6.4 Transporters at the Blood–Brain Barrier 214
- 7.7 Role of Drug Transporters in Chemotherapy Resistance 214
- 7.8 Pharmacogenomics of Drug Transporters: Implications for Clinical Drug Response 215
- Acknowledgments 215
- References 216

8 Transcriptional Regulation of Human Drug-Metabolizing Cytochrome P450 Enzymes 223

Zdenek Dvorak

- 8.1 Factors Affecting Drug-Metabolizing Cytochromes P450 223
- 8.1.1 Genetic Polymorphism 223
- 8.1.2 Physiological and Pathophysiological Factors 224
- 8.1.3 Environmental Factors 224
- 8.2 Transcriptional Regulation of CYP 224
- 8.2.1 Xenoreceptors, and Steroid and Nuclear Receptors 225
- 8.2.1.1 Aryl Hydrocarbon Receptor 225
- 8.2.1.2 Pregnane X Receptor 226
- 8.2.1.3 Constitutive Androstane Receptor 226
- 8.2.1.4 Steroid and Nuclear Receptors 227
- 8.2.2 Transcriptional Mechanisms 227
- 8.2.2.1 Direct Binding to the Gene Promoter 227
- 8.2.2.2 Indirect Binding to the Gene Promoter 227
- 8.2.2.3 Regulating the Regulator 228
- 8.2.3 Receptor Cross-Talk 228
- 8.2.3.1 Ligand Sharing 228
- 8.2.3.2 Response Element Sharing 228
- 8.2.3.3 Receptor Cascade 228
- 8.2.3.4 Coactivator Sharing 229
- 8.2.3.5 Metabolic Cross-Talk 229
- 8.2.4 Ligands–Agonists and Antagonists 229
- 8.3 Regulation of Drug-Metabolizing CYPs 230
- 8.3.1 CYP1A Subfamily 230
- 8.3.2 CYP1B1 232
- 8.3.3 CYP2A6 233
- 8.3.4 CYP2B6 234
- 8.3.5 CYP2C Subfamily 235
- 8.3.6 CYP3A Subfamily 236
- Acknowledgments 238
- References 238

9	Importance of Pharmacogenomics	259
	<i>Ulrich M. Zanger, Kathrin Klein, and Jessica Rieger</i>	
9.1	Introduction	259
9.2	Pharmacogenetic Polymorphisms	260
9.2.1	Lessons from Early Examples	260
9.2.2	Cytochrome P450 Polymorphisms	263
9.2.3	Polymorphisms in Further Drug-Metabolizing Enzymes	268
9.2.4	Polymorphic Drug Transporters	269
9.3	Polygenic and Multifactorial Aspects of Drug Metabolism Phenotype	270
9.3.1	Polygenic Inheritance: CYP1A2 and CYP3A4 Conundrums	270
9.3.2	Epigenetic Influences on Drug Metabolism	272
9.4	Genomics Technologies and Approaches	273
9.4.1	GWAS—A Matured Tool in Pharmacogenomics	274
9.4.2	Genetical Genomics: Identifying Novel Polymorphic ADME Genes	275
9.5	Conclusions	276
	References	276

Part Two Metabolism of Drugs 285

10	Introduction to Drug Metabolism	287
	<i>Ulrich M. Zanger</i>	
10.1	Introduction	287
10.2	Historical Aspects	287
10.3	Diversity of Drug Metabolic Pathways	288
10.4	Influence of Drug Metabolism on Pharmacological Activity	289
10.5	Biotoxification	290
10.6	Extrahepatic Drug Metabolism	290
10.7	Factors Affecting Drug Metabolism Activity	291
10.7.1	Genetic Polymorphism	291
10.7.2	Sex	292
10.7.3	Age	293
10.7.4	Influence of Diseases and Pathophysiological Factors	294
10.7.5	Environmental Influences	294
10.8	Conclusions	296
	References	296

11	Central Nervous System Drugs	301
	<i>Pierre Baumann and Christoph Hiemke</i>	
11.1	Introduction	301
11.2	Antidepressants	301
11.2.1	Tricyclic Antidepressants and Structurally Related Compounds	302
11.2.2	SSRIs	303
11.2.3	Other Recent Antidepressants	305

- 11.2.4 MAO Inhibitors 306
- 11.3 Antipsychotics 306
 - 11.3.1 Phenothiazines and Thioxanthenes 306
 - 11.3.2 Butyrophenones and Related Compounds 307
 - 11.3.3 Atypical Antipsychotics 307
- 11.4 Tranquillizers and Hypnotic Agents 309
- 11.5 Psychostimulants 311
- 11.6 Anticonvulsants and Mood Stabilizers 311
- 11.7 Agents for Dementia and Cognitive Enhancers 313
- 11.8 Antimigraine Drugs 313
- 11.9 Other Drugs 314
- 11.10 Conclusions 314
- References 315

- 12 Cardiovascular Drugs 331**
Stephan Riedmaier and Ulrich M. Zanger
- 12.1 Introduction 331
- 12.2 RAAS as a Target for Angiotensin-Converting Enzyme Inhibitors and AT₁ Receptor Blockers 331
 - 12.2.1 ACE Inhibitors 332
 - 12.2.2 ARBs 334
- 12.3 Adrenergic Receptor Agonists 337
 - 12.3.1 α_1 -Selective Adrenergic Receptor Agonists 337
 - 12.3.2 α_2 -Selective Adrenergic Receptor Agonists 338
 - 12.3.3 β -Selective Adrenergic Receptor Agonists 339
- 12.4 Adrenergic Receptor Antagonists 339
 - 12.4.1 α_1 -Selective Adrenergic Receptor Antagonists 339
 - 12.4.2 α_2 -Selective Adrenergic Receptor Antagonists 340
 - 12.4.3 β -Selective Adrenergic Receptor Antagonists 342
- 12.5 Diuretics 342
 - 12.5.1 Carbonic Anhydrase Inhibitors 344
 - 12.5.2 Osmotic Diuretics 344
 - 12.5.3 $\text{Na}^+ - \text{K}^+ - 2\text{Cl}^-$ Symport Inhibitors 345
 - 12.5.4 Thiazide or Thiazide-Like Diuretics 345
 - 12.5.5 Nonspecific Cation Channel Inhibitors 347
 - 12.5.6 Inhibitors of Renal Epithelial Na^+ Channels 347
 - 12.5.7 Mineralcorticoid Receptor Antagonists 348
- 12.6 Antiarrhythmics 349
 - 12.6.1 Calcium Channel Blockers 349
- 12.7 Anticoagulants 351
 - 12.7.1 Heparin 352
 - 12.7.2 Vitamin K Antagonists 352
 - 12.7.3 Antiplatelet Drugs 352
- 12.8 Cholesterol-Lowering Drugs 353
 - 12.8.1 Bile Acid Sequestrants 354
 - 12.8.2 Cholesterol Uptake Inhibitors 354

- 12.8.3 Fibrates 354
- 12.8.4 Statins 355
- References 357

- 13 Anticancer Drugs 365**
Matthias Schwab, Elke Schaeffeler, and Hiltrud Brauch
- 13.1 Introduction 365
- 13.2 Alkylating Drugs 365
- 13.2.1 Oxazaphosphorine (Cyclophosphamide, Ifosphamide) 365
- 13.2.2 Melphalan 366
- 13.2.3 Ethyleneimines (Thiotepa) 366
- 13.2.4 Busulfan 366
- 13.2.5 Methylhydrazines (Procarbazine) 367
- 13.3 Platinum-Containing Agents 367
- 13.4 Antimetabolites 367
- 13.4.1 Folic Acid Antagonist (Methotrexate) 367
- 13.4.2 Pyrimidine Analogs (5-Fluorouracil/Capecitabine/Tegafur) 368
- 13.4.3 Cytidine Analogs 368
- 13.4.3.1 Cytarabine and Gemcitabine 368
- 13.4.3.2 Azacitidine and Decitabine 369
- 13.4.4 Purine Analogs 369
- 13.4.4.1 6-Thiopurine Analogs 369
- 13.4.4.2 Fludarabine Phosphate 370
- 13.5 Natural Products 370
- 13.5.1 Vinca Alkaloids (Vincristine) 370
- 13.5.2 Taxanes (Paclitaxel, Docetaxel) 370
- 13.5.3 Camptothecin Analogs 371
- 13.5.3.1 Topotecan 371
- 13.5.3.2 Irinotecan 371
- 13.5.4 Antibiotics 371
- 13.5.4.1 Dactinomycin 371
- 13.5.4.2 Anthracyclines 372
- 13.5.4.3 Epipodophyllotoxins 372
- 13.6 Endocrine Therapy 372
- 13.6.1 Selective Estrogen Receptor Modulator (Tamoxifen) 372
- 13.6.2 Aromatase Inhibitors 373
- 13.7 Histone Deacetylase Inhibitor (Vorinostat) 373
- 13.8 Tyrosine Kinase Inhibitors 373
- 13.9 Proteasome Inhibitor (Bortezomib) 374
- References 374

- 14 Antimicrobial Agents 379**
Chantal Csajka, Oscar Marchetti, Oriol Manuel, Laurent Decosterd, and Amalio Telenti
- 14.1 Introduction 379

14.2	Pharmacokinetics/Pharmacodynamics of the Main Families of Antimicrobial Agents	380
14.2.1	Aminoglycosides	380
14.2.2	Vancomycin	382
14.2.3	β -Lactams	383
14.2.4	Antifungal Agents	386
14.2.5	Antiviral Agents (Non-HIV)	389
14.2.5.1	Drugs for Herpes Virus Infection	390
14.2.5.2	Drugs for Viral Hepatitis	390
14.2.5.3	Drugs against Respiratory Viruses	391
14.2.6	Anti-HIV Agents	391
14.3	Pharmacogenetics	393
14.4	Conclusions	397
	Acknowledgments	398
	References	398
15	Drugs against Acute and Chronic Pain	403
	<i>Andrew A. Somogyi and Janet K. Collier</i>	
15.1	Introduction	403
15.2	Acute Pain	403
15.2.1	Dexmedetomidine	403
15.2.2	Paracetamol/Acetaminophen	407
15.2.3	Nonsteroidal Anti-Inflammatory Drugs	408
15.2.3.1	Diclofenac	408
15.2.3.2	Flurbiprofen	408
15.2.3.3	Ibuprofen	408
15.2.3.4	Ketoprofen	409
15.2.3.5	Ketorolac	409
15.2.3.6	Meloxicam	409
15.2.3.7	Naproxen	409
15.2.4	Cyclooxygenase-2 Selective Inhibitors	410
15.2.4.1	Celecoxib	410
15.2.4.2	Etoricoxib	410
15.2.4.3	Parecoxib	410
15.3	Chronic Pain	410
15.3.1	Tricyclic Antidepressants	410
15.3.1.1	Amitriptyline	410
15.3.1.2	Nortriptyline	411
15.3.1.3	Imipramine	411
15.3.1.4	Desipramine	412
15.3.2	SNRIs	412
15.3.2.1	Duloxetine	412
15.3.2.2	Venlafaxine	412
15.3.3	SSRIs	413
15.3.3.1	Citalopram	413

- 15.3.3.2 Fluoxetine 413
- 15.3.3.3 Paroxetine 414
- 15.3.4 Ketamine 414
- 15.3.5 Antiepileptics 415
 - 15.3.5.1 Carbamazepine 415
 - 15.3.5.2 Valproate 415
- 15.3.6 Miscellaneous 415
 - 15.3.6.1 Gabapentin 415
 - 15.3.6.2 Pregabalin 415
 - 15.3.6.3 Tapentadol 415
- 15.3.7 Opioids 416
 - 15.3.7.1 Buprenorphine 416
 - 15.3.7.2 Butorphanol 416
 - 15.3.7.3 Codeine 416
 - 15.3.7.4 Dextromoramide 417
 - 15.3.7.5 Dextropropoxyphene 417
 - 15.3.7.6 Dihydrocodeine 417
 - 15.3.7.7 Alfentanil, Fentanyl, Sufentanil, and Remifentanil 417
 - 15.3.7.8 Heroin (Diamorphine (3,6-Diacetylmorphine)) 417
 - 15.3.7.9 Hydrocodone 418
 - 15.3.7.10 Hydromorphone 418
 - 15.3.7.11 Ketobemidone 418
 - 15.3.7.12 ι - α -Acetylmethadol 418
 - 15.3.7.13 Levorphanol 418
 - 15.3.7.14 Loperamide 418
 - 15.3.7.15 Methadone 419
 - 15.3.7.16 Morphine 419
 - 15.3.7.17 Nalbuphine 419
 - 15.3.7.18 Nicomorphine (3,6-Dinicotinylmorphine) 419
 - 15.3.7.19 Oxycodone 420
 - 15.3.7.20 Oxymorphone 420
 - 15.3.7.21 Pentazocine 420
 - 15.3.7.22 Pethidine 420
 - 15.3.7.23 Piritramide 420
 - 15.3.7.24 Tilidine 420
 - 15.3.7.25 Tramadol 421
- References 421

16 Drugs of Abuse (Including Designer Drugs) 429

Markus R. Meyer and Hans H. Maurer

- 16.1 Introduction 429
- 16.2 Classic Drugs of Abuse 432
 - 16.2.1 Morphine and Heroin 432
 - 16.2.2 Cocaine 432
 - 16.2.3 THC 433

- 16.2.4 Amphetamine/Methamphetamine 434
- 16.2.5 LSD 434
- 16.2.6 PCP 434
- 16.3 Designer Drugs of Abuse 435
 - 16.3.1 Amphetamine Derivatives 435
 - 16.3.1.1 Methylenedioxyamphetamines 435
 - 16.3.1.2 *p*-Substituted Amphetamines 437
 - 16.3.1.3 2,5-Dimethoxyamphetamines 438
 - 16.3.2 Phenethylamines (2Cs) 439
 - 16.3.2.1 2C-B 439
 - 16.3.2.2 2C-I 440
 - 16.3.2.3 2C-D 440
 - 16.3.2.4 2C-E 440
 - 16.3.2.5 2C-T-2 440
 - 16.3.2.6 2C-T-7 441
 - 16.3.2.7 Enzymes Involved in the Metabolism of 2,5-Dimethoxyamphetamines 441
 - 16.3.3 Cathinones 441
 - 16.3.3.1 Methylone 441
 - 16.3.3.2 Butylone 442
 - 16.3.3.3 Ethylone 442
 - 16.3.3.4 Mephedrone 442
 - 16.3.4 Phencyclidine Derivatives 443
 - 16.3.4.1 *N*-(1-Phenylcyclohexyl)-3-ethoxypropylamine (PCEPA) and *N*-(1-Phenylcyclohexyl)-3-methoxypropanamine (PCMPA) 443
 - 16.3.4.2 *N*-(1-Phenylcyclohexyl)propanamine (PCPr) 443
 - 16.3.4.3 *N*-(1-Phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and *N*-(1-Phenylcyclohexyl)-2-methoxyethanamine (PCMEA) 444
 - 16.3.4.4 Enzymes Involved in the Metabolism of Phencyclidine Derivatives 444
 - 16.3.5 Piperazines 444
 - 16.3.5.1 *N*-BZP 445
 - 16.3.5.2 1-(3,4-Methylenedioxybenzyl)piperazine (MDBP) 445
 - 16.3.5.3 1-(3-Trifluoromethylphenyl)piperazine (TFMPP) 445
 - 16.3.5.4 1-(3-Chlorophenyl)piperazine (mCPP) 446
 - 16.3.5.5 1-(4-Methoxyphenyl)piperazine (MeOPP) 446
 - 16.3.6 Pyrrolidinophenones 446
 - 16.3.6.1 α -Pyrrolidinopropiophenone (PPP) 447
 - 16.3.6.2 4'-Methoxy- α -pyrrolidinopropiophenone (MOPPP) 447
 - 16.3.6.3 Methylenedioxy- α -pyrrolidinopropiophenone (MDPPP) 447
 - 16.3.6.4 4'-Methyl- α -pyrrolidinopropiophenone (MPPP) 448
 - 16.3.6.5 4'-Methyl- α -pyrrolidinohexanophenone (MPHP) 448
 - 16.3.6.6 4'-Methyl- α -pyrrolidinobutyrophenone (MPBP) 449
 - 16.3.6.7 4'-Methyl- α -pyrrolidinovalerophenone (PVP) 449

- 16.3.6.8 3',4'-Methylenedioxypropylvalerone (MDPV) 449
- 16.3.7 Tryptamines 450
- 16.3.7.1 5-Methoxy-diisopropyl-tryptamine (5-MeO-DIPT) 450
- References 450

- 17 Nicotine Metabolism and its Implications 465**
Andy Z.X. Zhu and Rachel F. Tyndale
- 17.1 Introduction 465
- 17.2 Absorption and Distribution of Nicotine 465
- 17.2.1 Absorption 465
- 17.2.2 Distribution 466
- 17.3 Excretion of Nicotine 466
- 17.4 Metabolism of Nicotine 468
- 17.4.1 Primary Metabolites of Nicotine 468
- 17.4.2 Secondary Metabolites of Nicotine 470
- 17.4.3 Tertiary Metabolite of Nicotine 470
- 17.5 Sources of Variation in Nicotine Metabolism 471
- 17.5.1 Genetic 471
- 17.5.1.1 CYP2A6 and Nicotine C-Oxidation 471
- 17.5.1.2 Using the 3'-Hydroxycotinine:Cotinine Ratio as an *In Vivo* Probe for CYP2A6 Activity 471
- 17.5.1.3 Interethnic Variability in Nicotine C-Oxidation 476
- 17.5.1.4 Genetic Influences on Other Nicotine-Metabolizing Enzymes 476
- 17.5.2 Gender and Pregnancy 477
- 17.5.3 Age 478
- 17.5.4 Meals and the Chronopharmacokinetics of Nicotine 479
- 17.5.5 Xenobiotics 479
- 17.5.6 Smoking 480
- 17.5.7 Menthol 480
- 17.5.8 Other Factors 480
- 17.6 Implications of Variation in Nicotine Metabolism and CYP2A6 Activity 481
- 17.6.1 Variation in Nicotine Metabolism is Associated with Altered Smoking Behaviors 481
- 17.6.2 Variation in Nicotine Metabolism May Alter the Health Consequences of Smoking 481
- 17.6.3 Variation in Nicotine Metabolism Alters Smoking Cessation Outcomes 482
- 17.7 Conclusions 483
- Acknowledgments 483
- References 484

- 18 Metabolism of Alcohol and its Consequences 493**
Helmut K. Seitz and Sebastian Mueller
- 18.1 Introduction 493

- 18.2 Properties and Sources of Ethanol 494
- 18.2.1 Chemical Properties of Ethanol 494
- 18.2.2 Ethanol Content of Alcoholic Beverages 494
- 18.2.3 Ethanol Generation in the Human Body 494
- 18.3 Ethanol Absorption and Elimination 495
- 18.3.1 Ethanol Absorption and Ethanol Blood Levels 495
- 18.3.2 Calculation of Ethanol Elimination Using the Widmark Equation 496
- 18.4 Ethanol Metabolism 497
- 18.4.1 Ethanol Metabolism via ADH 497
- 18.4.2 Gastric FPM of Ethanol 502
- 18.4.3 Ethanol Metabolism via the MEOS 504
- 18.4.4 Ethanol Metabolism via Catalase 510
- 18.4.5 Nonoxidative Metabolism of Ethanol 510
- 18.4.6 Acetaldehyde Metabolism via ALDH 510
- Acknowledgments 511
- References 511

Part Three Metabolism of Natural Compounds 517

- 19 Introduction and Overview 519**
Michael Murray
- 19.1 Introduction 519
- 19.1.1 Sources and Functional Importance of Natural Products 519
- 19.1.2 Plant Products as Drugs: A Historical Perspective 520
- 19.1.3 Considerations with the Use of Natural Products as Drugs 520
- 19.1.4 Biotransformation of Natural Products 521
- 19.1.5 Classes of Natural Products 521
- 19.2 Terpenoids: A Structurally Complex Group of Natural Products 522
- 19.2.1 Terpenoid Biosynthesis 522
- 19.2.2 Biotransformation of Terpenoids 524
- 19.2.2.1 Monoterpenoids 524
- 19.2.2.2 Sesquiterpenoids 527
- 19.2.2.3 Diterpenoids 528
- 19.2.2.4 Triterpenoids 528
- 19.2.2.5 Triterpenoids 530
- 19.3 Other Classes of Natural Products 531
- 19.3.1 Biosynthesis of Polyketides, Shikimates, and Alkaloids 531
- 19.3.2 Biotransformation of Important Polyketides, Shikimates, and Alkaloids in Man 532
- 19.4 Summary and Conclusions 536
- Acknowledgments 536
- References 536

20	Flavonoids	543
	<i>Petr Hodek</i>	
20.1	Flavonoids–Plant Phytochemicals	543
20.1.1	Classification of Flavonoids and Their Physicochemical Properties	543
20.1.2	Biosynthesis of Flavonoids and Their Biological Function in Plants	545
20.2	Absorption and Metabolism of Flavonoids	545
20.2.1	Flavonoid Bioavailability	545
20.2.2	Metabolism of Flavonoids	547
20.2.2.1	Intestinal Metabolism	548
20.2.2.2	Decisive Role of Colonic Microflora	549
20.2.2.3	Metabolism in Liver	549
20.2.2.4	Flavonoid Excretion	550
20.2.3	Overall Flavonoid Fate in Organisms	551
20.2.3.1	Plasma Levels and Pharmacokinetics of Flavonoids	553
20.3	Interactions of Flavonoids with Mammalian Proteins with Possible Implications for Drug Metabolism	554
20.3.1	Plasma Proteins	554
20.3.2	ATP-Binding Proteins	555
20.3.2.1	MRPs	555
20.3.2.2	Kinases	556
20.3.3	Flavonoid-Binding Receptors	557
20.3.3.1	Estrogen Receptor	557
20.3.3.2	GABA-A Receptor	558
20.3.3.3	Aryl Hydrocarbon Receptor	558
20.3.4	Redox Enzyme Activity Modulation	559
20.3.4.1	Xenobiotic-Metabolizing Enzymes	560
20.3.4.2	LOXs, COXs, and XOs	561
20.4	Dietary Flavonoids–Health Issues	562
20.4.1	Antioxidant and Pro-Oxidant Properties	562
20.4.2	Antiviral, Antibacterial, and Antifungal Agents	563
20.4.3	Other Biological Activities of Flavonoids	564
20.4.4	Flavonoids as Nutraceuticals	565
20.4.4.1	Cytotoxic and Cytoprotective Effects	566
20.4.5	Flavonoid Interference with the Metabolism of Endo- and Xenobiotics	567
20.4.5.1	Flavonoid Impact on the Metabolism of Endogenous Compounds	568
20.4.5.2	Effect of Flavonoids on Carcinogen Activation	568
20.5	Flavonoid–Drug Interactions	570
20.6	Conclusion–Double-Edged Sword Properties of Flavonoids	573
	References	574
21	St John's Wort (<i>Hypericum perforatum</i> L.)	583
	<i>Miroslav Dostalek and Anna-Katarina Stark</i>	
21.1	The Name <i>Hypericum</i>	583

- 21.2 Chemical Constituents of *Hypericum perforatum* 583
- 21.3 Clinical Pharmacology of *H. perforatum* 587
 - 21.3.1 Antidepressive Activity 587
 - 21.3.2 Photodynamic Therapy and Cancer 587
 - 21.3.3 Antiviral Activity 587
 - 21.3.4 Other Pharmacological Activities 587
- 21.4 Pharmacokinetics and Pharmacokinetic Interactions of *H. perforatum* 588
 - 21.4.1 Phloroglucinols: Hyperforin 588
 - 21.4.2 Naphthodianthrone: Hypericin and Pseudohypericin 588
 - 21.4.3 Flavonoids: Rutin and Quercetin 589
- 21.5 *In Vitro* Studies 591
- 21.6 *In Vivo* Studies 592
- Acknowledgments 592
- References 603

- 22 Food Components and Supplements 611**
Alexandr Parlesak
 - 22.1 Introduction 611
 - 22.2 Food Contaminants 612
 - 22.2.1 Polycyclic Aromatic Hydrocarbons and Polycyclic Aromatic Amines 612
 - 22.2.2 Acrylamide 613
 - 22.2.3 Nitrosamines 614
 - 22.2.4 Fungal Toxins 614
 - 22.3 Vitamins 616
 - 22.3.1 Vitamin A, Retinoic Acid, and Carotenoids 616
 - 22.3.2 Vitamin D (Cholecalciferol and Ergocalciferol) 618
 - 22.3.3 Vitamin E (Tocopherol) 619
 - 22.3.4 Water-Soluble Vitamins (Thiamine and Riboflavin) 620
 - 22.4 Macronutrients 620
 - 22.4.1 Protein 620
 - 22.4.2 Fatty Acids 621
 - 22.4.3 Carbohydrates 622
 - 22.5 Secondary Plant Metabolites 622
 - 22.5.1 Grapefruit Juice, Naringenin, and Presystemic Drug Clearance by CYP3A4 622
 - 22.5.2 Inhibition of Metabolic Activation of Drugs by CYP3A4 623
 - 22.5.3 Secondary Plant Metabolites, CYP Modulation, and Intestinal Inflammation 623
 - 22.5.4 Parallel Consumption of Drugs and Inhibitors of Intestinal Drug Metabolism—Threats and Chances 624
 - 22.5.5 Glucosinolates and Allylsulfides 625
 - 22.5.6 Caffeine 626
 - 22.5.7 Cholesterol 626

- 22.6 Probiotics and Prebiotics in the Modulation of Drug Metabolism 628
- References 629

Part Four Metabolism of Unnatural Xenobiotics 637

- 23 Environmental Pollutants 639**
 - Marie Stiborova*
 - 23.1 Introduction—An Overview 639
 - 23.1.1 Types of Environmental Pollutants 640
 - 23.2 Overview of Environmental Pollutants 641
 - 23.2.1 Air Pollutants 641
 - 23.2.2 Water Pollutants 642
 - 23.2.3 Soil Pollutants 642
 - 23.3 Toxic and Hazardous Environmental Pollutants Interacting with Drug Metabolism 642
 - 23.3.1 Acetaldehyde 642
 - 23.3.2 Acetonitrile 643
 - 23.3.3 2-Acetylaminofluorene 643
 - 23.3.4 Acrolein 643
 - 23.3.5 Acrylamide 643
 - 23.3.6 4-Aminobiphenyl 644
 - 23.3.7 *o*-Anisidine 644
 - 23.3.8 Acrylonitrile (2-Propenenitrile) 644
 - 23.3.9 Arsenic and Arsenic Compounds 645
 - 23.3.10 Asbestos 645
 - 23.3.11 Antimony Compounds 646
 - 23.3.12 Benzene 646
 - 23.3.13 Benzidine 647
 - 23.3.14 1,3-Butadiene (Vinyl Ethylene) 647
 - 23.3.15 Cadmium Compounds 647
 - 23.3.16 Carbon Tetrachloride 648
 - 23.3.17 Carbon Monoxide 648
 - 23.3.18 Chloroform 649
 - 23.3.19 Chloroprene 649
 - 23.3.20 Cr (VI) Compounds 650
 - 23.3.21 Cobalt and Cobalt Compounds 650
 - 23.3.22 1,4-Dichlorobenzene 651
 - 23.3.23 1,3-Dichloropropene 651
 - 23.3.24 Dichloromethane 651
 - 23.3.25 1,1-Dimethylhydrazine 652
 - 23.3.26 Ethylene Oxide 652
 - 23.3.27 Formaldehyde 652
 - 23.3.28 Heptachlor 653
 - 23.3.29 Hexachlorobenzene 653

- 23.3.30 Hydrazine 654
- 23.3.31 Lead and Lead Compounds 654
- 23.3.32 Lindane (All Isomers) 655
- 23.3.33 Mercury Compounds 655
- 23.3.34 NO_x 656
- 23.3.35 Ozone 656
- 23.3.36 Parathion 656
- 23.3.37 Phthalates 657
- 23.3.38 Polycyclic Aromatic Hydrocarbons 657
- 23.3.39 Polychlorinated Biphenyls 658
- 23.3.40 Polychlorinated Dioxins and Furans 658
- 23.3.41 Styrene and Styrene Oxide 659
- 23.3.42 Sulfur Dioxide 659
- 23.3.43 Tetrachloroethylene (Tetrachloroethene, Perchloroethylene) 660
- 23.3.44 Vinyl Chloride 660
- 23.4 Summary 660
- References 661

- 24 Environmental Estrogens 671**
Miroslav Machala and Jan Vondráček
- 24.1 Introduction 671
- 24.2 Estrogen Receptor Signaling Pathways 672
- 24.3 Agonistic/Antagonistic Effects of Xenobiotics on ERs 673
- 24.4 Effects of EDCs on Biosynthesis and Metabolism of Estrogens 676
- 24.5 Case of Polychlorinated Biphenyls 677
- 24.6 Conclusions 678
- References 679

- 25 Biotransformation of Insecticides 685**
Corie A. Ellison, Alice L. Crane, and James R. Olson
- 25.1 Introduction to Insecticides 685
- 25.1.1 Organophosphate Insecticides 685
- 25.1.2 Carbamate Insecticides 687
- 25.1.3 Pyrethroid Insecticides 687
- 25.1.4 Organochlorine Insecticides 688
- 25.2 Metabolism of Insecticides 688
- 25.2.1 Hepatic Phase I Enzymes Involved in Biotransformation of Insecticides 688
- 25.2.1.1 Cytochrome P450s 688
- 25.2.1.2 Flavin-Containing Monooxygenases 691
- 25.2.1.3 Others 692
- 25.2.2 Phase II Metabolism of Insecticides 692
- 25.3 Extrahepatic Metabolism of Insecticides 693
- 25.4 Factors Affecting Metabolism 694
- 25.4.1 Route of Exposure 694

25.4.2	Interaction of Xenobiotics	695
25.4.3	Impact of Age, Gender, Species, and Pathology	695
25.4.4	Interindividual Genetic Variability	696
25.5	Conclusions	697
	Note	697
	References	697
	Index	703